The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
Küçük Resim Yok
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Akad Doktorlar Yayinevi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.
Açıklama
Anahtar Kelimeler
Chronic Myeloid Leukemia, Dasatinib, Treatment Dosage, Chronic Myelogenous Leukemia, Tyrosine Kinase Inhibitor, Nilotinib Formerly Amn107, Chronic-Phase, Bcr-Abl, Imatinib Resistance, Therapy, Failure, Nonadherence, Intolerance
Kaynak
Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
22
Sayı
1
